Ind-Swift Limited (INDSWFTLTD)

27.61

INR
-1.88(-6.38%)
As of December 13, 2024 9:59:00 AM
No price data available

Ind-Swift Limited Share Price Information

24 hour Low and High

Low: 27.29
High: 29.9

All time High

32.50

Price Change 1h

+₹-1.88 +-6.38%

Price Change 1d

+₹-1.88 +-6.38%

Price Change 1w

+₹6.83 +32.87%

Ind-Swift Limited Market Information

Exchange

NSE

Market Cap

₹113.32 Cr

About Ind-Swift Limited Share

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

1054

CEO

Dr. Gopal Munjal M.D.

Revenue (2023)

NA

NA

Country of Origin

India

Key Highlights

  • Ind-Swift Limited (NSE:INDSWFTLTD): Does The Earnings Decline Make It An Underperformer?
  • IndiaRF Fund borrows Rs 700 crore from Axis Bank for Ind Swift buyout
  • What Percentage Of Ind-Swift Limited (NSE:INDSWFTLTD) Shares Do Insiders Own?
  • INDSWFTLAB Share Price Target 2024, 2025, 2026 To 2030

FAQs

Ind-Swift Limited (INDSWFTLTD)

27.61

INR
-1.88(-6.38%)
As of December 13, 2024 9:59:00 AM
No price data available

Ind-Swift Limited Share Price Information

24 hour Low and High

Low: 27.29
High: 29.9

All time High

32.50

Price Change 1h

+₹-1.88 +-6.38%

Price Change 1d

+₹-1.88 +-6.38%

Price Change 1w

+₹6.83 +32.87%

Ind-Swift Limited Market Information

Exchange

NSE

Market Cap

₹113.32 Cr

About Ind-Swift Limited Share

Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. The company offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names. It also offers medicines for various therapeutic comprising gynaecology, pediatrics, dermatology, and other generic medicines under the Anin, Suprox, Cozy, Distone, and Oliade name. In addition, the company provides antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-depressant, anti-allergic, anti- infective, neurology, and oncology. Ind-Swift Limited provides Ayurvedic products, as well as contract research and manufacturing services. The company exports its products, as well as licenses its products to Europe, Australia, Canada, South Africa, and Russia. Swift Limited was founded in 1983 and is based in Chandigarh, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

1054

CEO

Dr. Gopal Munjal M.D.

Revenue (2023)

NA

NA

Country of Origin

India

Key Highlights

  • Ind-Swift Limited (NSE:INDSWFTLTD): Does The Earnings Decline Make It An Underperformer?
  • IndiaRF Fund borrows Rs 700 crore from Axis Bank for Ind Swift buyout
  • What Percentage Of Ind-Swift Limited (NSE:INDSWFTLTD) Shares Do Insiders Own?
  • INDSWFTLAB Share Price Target 2024, 2025, 2026 To 2030

FAQs